BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

Benzinga · 2d ago
BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.